Testosterone therapy modestly improves sexual function, corrects anemia, and increases bone density in older men with hypogonadism.
Risks include increased venous thromboembolism, clinical fractures, and atrial fibrillation; no significant increase in major cardiovascular events or prostate cancer observed in trials to date.
Therapy should be reserved for men with unequivocally low testosterone levels and persistent symptoms after careful diagnostic workup.
